JAC Advance Access published online on February 21, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl040
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 The National Reference Center for Neisseria gonorrhoeae, Laboratory of Bacteriology, Hellenic Pasteur Institute, Athens, Greece
* To whom correspondence should be addressed. Objectives: Surveillance data concerning antimicrobial susceptibilities of Neisseria gonorrhoeae isolated in Greece during the 11 year period 1994-2004 are presented. Methods: Antimicrobial susceptibilities of all gonococcal isolates received by the Greek National Reference Center for N. gonorrhoeae during the study period were determined in terms of MICs using Etest. Trends in yearly isolation frequencies by susceptibility category were estimated for defining significant changes in overall susceptibility figures. Results: Cefotaxime and spectinomycin retained undiminished activity against all isolates throughout the study period. High rates of resistance and intermediate susceptibilities were noticed for penicillin, tetracycline and erythromycin, and even for norfloxacin and ciprofloxacin. A substantial portion (16.5%) of the gonococcal samples consisted of multiresistant strains exhibiting resistance to two or more agents of different antibiotic classes. Although annual rates of low-level chromosomal resistance decreased, high-level resistance owing to the presence of penicillin- and tetracycline-resistance plasmids increased. Fluoroquinolone resistance also showed a significant increasing trend after 1996, reaching a peak rate of 11.3% in 2004. Conclusion: Third-generation cephalosporins and spectinomycin should be considered as first-choice drugs for the empirical treatment of gonorrhoea in Greece.
Received November 29, 2005
Revised January 27, 2006
Accepted January 27, 2006
Brief report
Antimicrobial susceptibility of Neisseria gonorrhoeae in Greece: data for the years 1994-2004
Maria Stathi 1,
Alexandros Flemetakis 2,
Vivi Miriagou 1,
Helen Avgerinou 2,
Kyriakos P. Kyriakis 1,
Antonios N. Maniatis 3,
and
Eva Tzelepi 1 *
2 Microbiology Laboratory of the ‘Andreas Sygros’ Hospital for Skin and Venereal Diseases, Athens, Greece
3 Department of Medical Microbiology, University of Thessaly, Larissa, Greece
Eva Tzelepi, E-mail: tzelepi{at}pasteur.gr
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. W. Tapsall, E. A. Limnios, D. Murphy, and on behalf of the Australian Gonococcal Surveillanc Analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997 2006 J. Antimicrob. Chemother., January 1, 2008; 61(1): 150 - 155. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bala, K. Ray, S. M. Gupta, S. Muralidhar, and R. K. Jain Changing trends of antimicrobial susceptibility patterns of Neisseria gonorrhoeae in India and the emergence of ceftriaxone less susceptible N. gonorrhoeae strains J. Antimicrob. Chemother., September 1, 2007; 60(3): 582 - 586. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. C. Martin, S. Hoffmann, C. A. Ison, and on behalf of the European Surveillance of Sexually European Surveillance of Sexually Transmitted Infections (ESSTI): the first combined antimicrobial susceptibility data for Neisseria gonorrhoeae in Western Europe J. Antimicrob. Chemother., September 1, 2006; 58(3): 587 - 593. [Abstract] [Full Text] [PDF] |
||||
